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background: Female cancer patients are offered ‘banking’ of gametes before starting fertility-threatening cancer therapy. Transplants
of fresh and frozen ovarian tissue between healthy fertile and infertile women have demonstrated the utility of the tissue banked for restor-
ation of endocrine and fertility function. Additional methods, like follicle culture and isolated follicle transplantation, are in development.
methods: Specialist reproductive medicine scientists and clinicians with complementary expertise in ovarian tissue culture and transplan-
tation presented relevant published literature in their ﬁeld of expertise and also unpublished promising data for discussion. As the major aims
were to identify the current gaps prohibiting advancement, to share technical experience and to orient new research, contributors were
allowed to provide their opinioned expert views on future research.
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results: Normal healthy children have been born in cancer survivors after orthotopic transplantation of their cryopreserved ovarian
tissue. Longevity of the graft might be optimized by using new vitriﬁcation techniques and by promoting rapid revascularization of the
graft. For the in vitro culture of follicles, a successive battery of culture methods including the use of deﬁned media, growth factors
and three-dimensional extracellular matrix support might overcome growth arrest of the follicles. Molecular methods and immunoassay
can evaluate stage of maturation and guide adequate differentiation. Large animals, including non-human primates, are essential working
models.
conclusions: Experiments on ovarian tissue from non-human primate models and from consenting fertile and infertile patients beneﬁt
from a multidisciplinary approach. The new discipline of oncofertility requires professionalization, multidisciplinarity and mobilization of
funding for basic and translational research.
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Introduction
The banking of ovarian tissue has become widespread in countries that
have already well-established fertility centres (Jeruss and Woodruff,
2009). Some research programmes are exploring small adaptations
of conventional cryopreservation methods applied speciﬁcally to
ovarian tissue. Despite the fact that there has been a growing interest
in banking ovarian tissue, with samples collected from several hundred
patients, there are very few research initiatives on how to ensure the
function of the thawed tissue once patients return with fertility treat-
ment requests. Major advances in this technology have occurred in the
past 6 months and a number of transplants in cohorts of infertility
patients provide a rationale for banking cancer tissue and transplants
(Silber et al., 2005, 2008b; Silber and Gosden, 2007). Thus far,
approximately 30 autotransplantations have led to the birth of eight
healthy children, which is a very encouraging evolution of the tech-
nique (Donnez et al., 2004; Meirow et al., 2005; Demeestere et al.,
2007; Andersen et al., 2008; Silber et al., 2008b). The advantage of
this technology is that the patient will have restoration of both endo-
crine and fertility function. The disadvantage is that some cancers have
an elevated risk of metastatic spread to the ovary which may
re-introduce aggressive cancer cells to the recent survivor of their
disease. Thus, additional methods for use of the stored ovarian
tissue are needed to minimize risk of cancer potentiation, whereas
maximizing the likelihood of a take home baby.
In contrast, research efforts to establish efﬁcient in vitro culture
methods for growing follicles at various stages have lagged, primarily
due to the inability to access primate (human and non-human)
tissues. There were very few original research articles published in
the last 2–3 years on this topic, which suggests that barriers to
tissue acquisition, low levels of research funding and gaps in our knowl-
edge about early follicle growth contribute to this phenomenon.
Indeed, the number of institutes worldwide focusing on the culture
of human tissue can be counted on one hand and addressing the bar-
riers will signiﬁcantly increase the pace and quality of research that is
urgently needed to improve the future fertility of cancer patients
(Jeruss and Woodruff, 2009). The most important need is for
robust in vitro follicle culture methods as an alternative to homologous
transplantation, as the risk for re-introducing cancer cells via the trans-
plant can pose signiﬁcant and undue risk to the patient. The growth of
follicles in vitro, starting from a primordial follicle and ending in the pro-
duction of an ovulatory follicle with a developmentally competent
oocyte, has only been achieved in mice thus far. The mouse model
demonstrates that long-term culture in vitro is compatible with
healthy offspring (O’Brien et al., 2003). Proactive experiments in
mice using different in vitro culture methodology have shown that long-
term culture of follicles does not harm the primary imprinting process
(Anckaert et al., 2009a). The mouse model has also been very valu-
able for understanding some basic principles of follicle assembly,
initiation of follicle growth and the role of speciﬁc growth and differen-
tiation factors (for reviews see Van den Hurk and Zhao, 2005; Picton
et al., 2008).
However, the physical and anatomical differences in the ovaries of
humans, cows, sheep, pigs and mice make it very difﬁcult to apply the
successful culture method used for growing mouse primordial (Eppig
and O’Brien, 1996) or primary follicles (Lenie et al., 2004) to larger
species (Smitz and Cortvrindt, 2002). Overcoming the growth arrest
and follicle death observed in current in vitro culture systems requires
a better comprehension of the physiology of follicle growth initiation,
the interplay of important growth factors, the basic metabolic needs of
early growing follicles and the physical environment of the follicle.
Due to the limited availability of human and primate ovarian tissue
for research, follicle culture technology has progressed more quickly in
some domestic animals, such as the cow, sheep, goat and pig, than in
primates and humans. The data generated from these animal models
are valuable for translational and clinical research, as human tissue is
less accessible. Research in non-human primate models is also
scarce, although it will be necessary in order to identify the optimal
culture protocol for human follicles. Similarities in the physiology of fol-
liculogenesis and in the aetiology of common gynaecological diseases
in primates (D’Hooghe et al., 2009) could justify their preferential
use as a model to more rapidly advance the work done with human
tissues.
Outside of their natural environment, follicles must cope with phys-
ical restrictions such as oxygen tension, temperature and uptake of
nutrients. Such complex problems have pushed ovarian follicle cultur-
ists to seek help from tissue engineers. Furthermore expertise in basic
physiology and biochemistry is of great value when designing and
implementing artiﬁcial matrices and monitoring basic metabolite con-
sumption from conditioned media. Some very promising initial data
on the use of new matrices in human and non-human primate follicle
culture are presented in this synopsis (Xu et al., 2009a, b). Obser-
vations from the most recent experiments using this matrix have intro-
duced new concepts in follicle biology; in particular, these studies have
challenged the premise that hormones are the only factors that
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control follicle development; rather, that the three-dimensional (3D)
architecture of the oocyte and surrounding somatic cells are critical
to the appropriate development of the oocyte. Further, this work
shows that the physical environment of the ovary is a regulating
force and this biomechanical signal can be pheno-copied by an appro-
priate support matrix (West-Farrell et al., 2009).
This manuscript brings together data and opinions from directors of
well-established American and European research laboratories who
are recognized leaders in their ﬁeld. It gives a factual overview of
where female fertility preservation and oncofertility research stands
today and identiﬁes challenges and new directions for the ﬁeld in
the near future.
Methods
Contributors to this article agreed to focus on one particular area of their
expertise within the larger topics of either follicle culture/oocyte matu-
ration or ovarian tissue transplantation. The main goal of this article was
not to extensively review all existing literature on each topic, but rather
to provide a concise overview of where the ﬁeld stands today and the
current opinion of experts in the ﬁeld. Contributors were asked to pin-
point some relevant research areas for the near future and were encour-
aged to discuss any new unpublished data from their own research. The
article aims to provide ESHRE and its readership with an unbiased view
of where the ﬁeld stands today and to indicate new directions that
might advance the ﬁeld.
All contributors have been performing research in the area of ovarian
function and assisted reproductive technologies and have published exten-
sively on their research. The panel members were representatives of Euro-
pean and American Academic Reproductive Research Centres and their
work reﬂects current practise in their home countries. It was decided
that the article would include rich and diverse expertise from scientists
working with large mammalian models (cow, sheep, primate, cat) as the
basis for developing translational and clinical methodologies, and in
order to discuss the potential use of current technologies for the preser-
vation of endangered animal species. All members of the panel had been
invited by ESHRE’s Task Force on Basic Reproductive Science.
Although it is recognized that the work on rodent species has, and is,
playing a tremendously important role for our understanding of reproduc-
tive physiology, the organizers chose not to include experts working with
this model as it was a pre-set goal of the panel to focus on particular pro-
blems with culture and transplantation of human ovarian tissue. Neverthe-
less, proper referencing of work performed with the mouse model and
with certain knockout models was included in this article. Although the
technologies described in this article are intended to be used on tissues
and cells that will be cryopreserved, the panel preferred not to expand
on cryopreservation or vitriﬁcation technologies, as most members of
the panel are self-described users of the technology rather than experts
in this research area. Where applicable, appropriate referencing of cryo-
preservation research was used.
Results
Ovarian tissue culture techniques
Models for ovarian cortical tissue culture: from mouse to large
mammalian species
The production of one live mouse in 1996 from an oocyte grown
entirely in vitro showed that oocyte development from the primordial
follicle stage to the stage of developmental competence is possible in
in vitro culture (Eppig and O’Brien, 1996). This inspired the develop-
ment of methods for culturing primordial follicles from cattle and
baboons (Wandji et al., 1996a, b; Braw-Tal and Yosseﬁ, 1997;
Wandji et al., 1997). Eppig and O’Brien used a two-step culture
system, comprised of an 8-day culture of whole newborn mouse
ovaries, with primordial follicles just beginning to form, followed by
enzymatic dissociation of the ovary, and isolation and further culture
of oocyte–granulosa cell complexes from the secondary follicles
that had developed during the 8-day organ culture. Subsequent
efforts improved the culture system and produced multiple, normal
offspring (O’Brien et al., 2003). These techniques work well for
mice because their follicles form during the ﬁrst few days after birth,
providing an ovary with a fairly uniform population of primordial fol-
licles. In addition, the ovaries are small enough to be cultured intact,
and soft enough to be dissociated enzymatically.
In contrast, in primates and most domestic species, follicles form
over a number of weeks during fetal life, the ovaries are too large
to be organ-cultured, and the stromal tissue is tough, making enzy-
matic dissociation without damage to oocytes difﬁcult (Wandji et al.,
1996a). To avoid these problems, an in vitro system was developed
for culturing small pieces of ovarian cortex obtained from fetal
bovine and baboon ovaries during the last third of gestation. Fetal
ovarian cortex is rich in primordial follicles, since massive follicular
attrition has yet to occur, and the tissue is much softer than adult
ovarian tissue, facilitating dissection of the cortex from the inner
medulla. Cortical pieces were cultured in Waymouth’s MB 752/1 sup-
plemented with antibiotics, pyruvic acid (25 mg/l) and ITSþ [6.25 mg
insulin, 6.25 mg transferrin and 6.25 ng selenium plus 1.25 mg bovine
serum albumin (BSA) and 5.35 mg linoleic acid/ml]. In this medium,
primordial follicles of fetal baboons and fetal or adult cattle activate
to become primary follicles within the ﬁrst 2 days of culture and fol-
licular and oocyte growth ensues (Wandji et al., 1996b, 1997;
Braw-Tal and Yosseﬁ, 1997). Initially this activation was considered
to be ‘spontaneous’ because the same medium and culture conditions
promoted an apparently normal percentage of follicles to be activated
in the study by Eppig and O’Brien (1996). Because almost all the
bovine and baboon follicles activated in medium with ITSþ, this
system is not appropriate for studying factors that might promote acti-
vation in vivo, but it was used to show that anti-Mullerian hormone
(AMH) can inhibit activation and growth of primary follicles in
bovine cortical pieces (Cushman and Fortune, 2003 and unpublished
results). In more recent studies, culturing bovine cortical pieces in
TSþ (i.e. ITS without insulin) maintained follicles at the primordial
stage for at least 10 days, implicating insulin as an activator of primor-
dial follicles in cattle. Culturing cortical pieces in TSþ has provided a
new culture system that allows the testing of other putative follicle
activators and use of this system has thus far suggested a role for kit
ligand in follicle activation in cattle (Muruvi and Fortune, 2009).
Although bovine and baboon follicles activate readily in the cortical
culture systems detailed above, very few primary follicles progress to
the secondary follicle stage (i.e. follicles with a theca layer surrounding
two or more layers of granulosa cells with no antral cavity). Attempts
to stimulate the primary to secondary follicle transition by adding fetal
bovine serum (FBS), follicle-stimulating hormone (FSH) or activin to
the culture medium or by lowering the oxygen tension in the
system detailed above were found not to be effective (Fortune
et al., 1998, 1999, 2000; Gigli et al., 2006). These negative results
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led to the development of an ‘in ovo’ culture system, in which cortical
pieces from fetal cattle or baboons were grafted beneath the chorioal-
lantoic membrane (CAM) of 6-day-old chick embryos, to test the
hypothesis that they would become vascularized and that this would
allow not only activation, but also development to the secondary
stage. Although the grafts vascularized rapidly and remained healthy
until their removal 10 days later, follicle activation did not occur
(Cushman et al., 2002). Further transplantation studies with whole
mouse ovaries provided evidence that the AMH secreted by the
gonads of male and female chick embryos (Hutson et al., 1981;
Teng, 1987; di Clemente et al., 1992) inhibits activation of mouse pri-
mordial follicles in ovo, since follicles in mouse ovaries lacking the AMH
type II receptor activated in ovo, whereas follicles in wild type ovaries
did not (Gigli et al., 2005). CAM-grafting of bovine cortical pieces after
gonadectomy of the host chick embryo also allowed activation, provid-
ing indirect evidence that AMH is responsible for the lack of activation
in bovine and baboon cortical pieces in ovo (Gigli et al., 2005). In the
future, the in ovo model could be used to test putative stimulators of
activation to determine which can overcome the inhibitory effect of
AMH when applied to a CAM graft of ovarian tissue, but such exper-
iments are technically difﬁcult.
In summary, a new in vitro culture system for bovine ovarian cortical
pieces has been developed that can maintain follicles in the primordial
stage. The culture system can be used to identify follicle activators, and
insulin and kit ligand have thus far been identiﬁed. In vivo activation is
probably regulated by a balance between stimulatory and inhibitory
factors impinging on an individual follicle and the in vitro culture
system can also be used to test the effects of putative inhibitors,
such as AMH, on the action of various stimulators. The in vitro
system is not very effective at promoting development to the second-
ary follicle stage; however, an important goal is to determine how that
might be achieved. Follicles in whole newborn mouse ovaries quickly
reach the secondary stage under similar culture conditions, so it is
important to study species that are good models for human follicular
development, such as cattle and non-human primates. In the in ovo
culture system, follicles are held at the primordial stage by circulating
AMH and this system could be used to test various factors for their
ability to overcome the inhibition by AMH and to stimulate the
primary to secondary transition. The drawbacks of this culture
system are that it is only practical to leave the grafts in place for
about 10 days because of developmental changes to the CAM, and
the techniques are difﬁcult to master.
Growing human oocytes from primordial follicles
The development of a culture system for human tissue has always
been perceived as being problematic because of the prolonged
period of follicle development required. Recent work from Telfer’s
lab (Telfer et al., 2008) has shown that human primordial follicles
grow well within mechanically loosened cortical pieces, which
contain growing follicles with the underlying stroma removed, and
can develop to multilaminar pre-antral (secondary) stages within 6
days. The culture conditions in this new system differ from those
described in previous studies (Hovatta et al., 1997, 1999) as no
serum is present and no supporting matrix is used. Most of the under-
lying stromal tissue is removed so that the cultured pieces consist of
predominantly ovarian cortex containing primordial and primary fol-
licles. Multilaminar (pre-antral) follicles grown within human ovarian
cortical strips can be isolated and have the potential to grow to the
antral stage of development if cultured individually within a total
culture period of 10 days (Telfer et al., 2008). This time scale makes
the complete in vitro development of oocytes from human tissue a
practical and viable prospect. However, whether this altered growth
rate affects subsequent oocyte development is a question that
needs to be addressed.
It is assumed that complete follicle development from primordial to
the pre-ovulatory stage in human takes up to 8 months and Gougeon
(1986) calculated the time needed for a follicle to grow from the
primary to the pre-ovulatory stage to be 84 days. However, there is
no good evidence to show that this is a continuous period of
growth; indeed, it is likely that follicles grow in vivo in a ‘start-stop’
manner in response to local inﬂuences. This hypothesis is supported
by studies showing that advanced-stage follicles can arrest the
growth of follicles at the pre-antral stage without compromising
their subsequent ability to proceed further (Mizunuma et al., 1999).
Studies on the underlying molecular mechanisms regulating the
initiation of follicle development (Foxo3 and Pten knockout studies)
have shown that despite global activation of follicles, the rate at
which follicles develop differs (i.e. some initiated follicles take days
to reach antral stages although others take weeks or even months;
Castrillon et al., 2003; Reddy et al., 2008). Studies in which the rate
of granulosa cell division has been altered in vivo (e.g. by deletion of
Pten in murine granulosa cells), resulted in rapid follicular growth
but had no effect on fertility (Fan et al., 2008). Therefore, it appears
that oocyte development can be supported within a rapidly developing
follicle. Indeed, this ‘accelerated’ growth has been demonstrated in
other (non-human) culture systems and fully grown oocytes have
been obtained (porcine: Wu et al., 2001; bovine: Telfer et al., 2000;
Thomas et al., 2003a for review). The challenge now is to deﬁne
the in vitro conditions that facilitate a rate of growth that supports
normal oocyte development, and current work in Telfer’s lab is focus-
ing on this (Johnson et al., 2009; Telfer et al., 2009).
Cortical strip culture removes follicles from the in vivo endocrine
and paracrine processes regulating growth rate; however, follicles
will still be subject to the effect of follicle interactions and the inﬂuence
of stromal cell factors. It is clear that tissue shape and stromal density
are important factors that regulate follicle growth initiation in vitro, as
solid cubes of cortical tissue show a lower rate of growth initiation
(Hovatta et al., 1997). In contrast, when stromal cells are removed
and the tissue is cultured as ﬂattened ‘sheets’, the initiation rate is
greater and follicles grow faster (Telfer et al., 2008). The physical
environment of the follicles within the cortical tissue affects their
response to stimulatory and inhibitory factors and therefore inﬂuences
their ability to grow (McLaughlin and McIver, 2009).
Once follicle growth is initiated within the strip, the follicles can
develop to multilaminar stages; at this point, the cortical strip environ-
ment becomes inhibitory to further growth. Therefore, strip culture
cannot support optimal development of all stages, and a multi-step
culture system is required to support complete development
(Fig. 1). Pre-antral follicles can be mechanically isolated from the
cortex culture system after 6 days and placed within an individual
culture system for further development to antral stages (Telfer
et al., 2008). Conditions to support development of isolated follicles
have been deﬁned in bovine systems (McCaffery et al., 2000;
Thomas et al., 2001, 2003a, b; Walters et al., 2006; Thomas et al.,
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2007) and this work formed the basis for optimising culture conditions
for isolated human follicles (Telfer et al., 2008). Key factors at this
stage are activin A and FSH (Telfer et al., 2008) and it will be important
to determine the optimal timing and concentrations of their combined
delivery during the culture period.
Further study is required to evaluate whether manipulating key sig-
nalling pathways such as PTEN and mTOR might be an original way to
maximize in vitro yields of follicles from an ovarian tissue piece.
Essential hormones and growth factors for growing human follicles
in vitro
Human ovarian follicle culture techniques have been developed since
the early 1990s, with the ultimate goal of achieving mature oocytes
from thawed tissue collected and frozen before initiation of fertility-
threatening therapies, such as chemotherapy or radiation therapy.
Research on the in vitro growth of follicles and maturation of
oocytes has offered the additional opportunity to study the factors
controlling human follicular development (for review, see Van Den
Hurk and Zhao, 2005; Sadeu et al., 2008). Effects of hormones and
growth factors tested in in vitro follicle culture are shown in Table I.
Culture conditions. In the earliest studies, FBS or human serum-
containing medium was used, but for safety reasons it was soon
replaced by deﬁned media substituted with human serum albumin
(HSA) and a combination of insulin, selenium and transferrin (ITS).
Many basal culture media were compared in the early studies, and
since then, alpha minimal essential medium (MEM) has been used
predominantly. For clinical maturation cultures, a good manufacturing
practices (GMP) grade culture medium is needed. A clinical grade ker-
atinocyte medium was used by Sadeu and Smitz (2008). The human
recombinant forms of hormones and growth factors should be used
when available: a central repository of hormones and grow factors
would facilitate the comparability of results from different laboratories.
Factors that prevent apoptosis have also been added, such as ascorbic
acid, cyclic GMP and cyclic AMP (Scott et al., 2004a).
As the vast majority of oocytes exist within primordial follicles in
ovarian cortical tissue, the culture setup should be designed to
support growth initiation from this earliest follicle stage. As in animal
experiments, the initiation of growth of follicles in cortical tissue is gen-
erally successful (Hovatta et al., 1997). Isolation of the follicles after
growth initiation is a possible strategy (Telfer et al., 2008). Isolated fol-
licle culture has been performed in small inserts with an extracellular
cellular matrix (ECM) coating (human placental Matrigel) or without
matrix, or isolated follicles may also be cultured on plastic in 24-well
plates. For clinical purposes, clinical grade xeno-free, serum-free
medium has to be used and follicle growth in this medium has been
shown to be feasible (Scott et al., 2004b).
Animal models, particularly the sheep and bovine models, have pro-
vided a basis for human follicle culture studies (Newton et al., 1999;
Gutierrez et al., 2000). For setting up human ovarian tissue culture
models, researchers have utilized various sources of tissue as listed
in Table II. No difference in culture results has been observed
between fresh or frozen-thawed tissue. Culture of ovarian tissue is a
suitable way to evaluate the quality of the freezing and thawing
Figure 1 Multi-step culture system to support human follicle development in vitro. (a) Diagram showing steps involved in the culture of human
primordial follicles to antral stages (i– ii) and removal of oocyte granulosa cell complexes (OGCs) for placement in alginate bead/membrane
(iii) for further growth and development and subsequent IVM [as proposed by Telfer’s lab (Telfer and McLaughlin, 2007)]. Human follicles can be
developed from primordial (b) to pre-antral (c) and antral stages (d) in serum free medium (Telfer et al., 2008).
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procedures. It remains unclear whether it is worthwhile to use ovarian
tissue from women over 38 years of age and the same question
remains as to the utility of ovarian tissue that had already been
treated for 1–2 weeks by chemotherapy.
Evaluation of cultured follicle outcomes. Histological evaluation has
always been the primary approach to assessing cultured follicles.
Optimal ﬁxation of the ovarian tissue can be achieved with Bouin’s
ﬁxative, which ﬁxes the oocytes without causing shrinkage and
enables evaluation of the tissue and oocyte general morphology.
Parameters of histological evaluation include: assessing follicular
density per square mm of tissue; measuring the diameter of the
oocyte and follicle and the thickness of the zona pellucida; counting
the layers of granulosa cells; and noting the presence of theca cells.
If immunohistochemistry (IHC) is intended, a portion of the tissue
can be ﬁxed in paraformaldehyde. Electron microscopy gives a more
accurate evaluation of the tissue after freezing and culture, but is
extremely laborious. Functionality can be tested using cell proliferation
stains by IHC. Hormone production, particularly estradiol (E2), can be
measured in the culture medium. Follicle development can now be
evaluated at the molecular level with gene expression analyses, quan-
titative real-time polymerase chain reaction (PCR) and microarrays.
Conclusions: growth factors and hormones for follicle culture. FSH, insulin,
activin A and growth and differentiation factor 9 (GDF9) promote fol-
licular development and survival. AMH inhibits the initiation of growth
of primordial follicles. Multi-step culture followed by in vitro maturation
(IVM) of the cumulus-enclosed oocyte will be needed to obtain ferti-
lizable oocytes (Fig. 1).
The importance of extracellular matrix in in vitro follicle culture
Introduction to ECM composition and its regulation. In discussions of
factors that drive ovarian follicle development, hormones and
growth factors acting by endocrine, paracrine and autocrine
.............................................................................................................................................................................................
Table I Hormones and growth factors used in the culture of follicles from fresh and frozen-thawed human ovarian tissue.
Article Hormone/growth
factor
Fresh
versus
frozen
Stage in
culture
Culture duration Observed outcomes
Roy and Treacy
(1993)
FSH, FCS Fresh Pre-antral to early
antral
4 days Increased growth, steroid production,
antrum formation
Hovatta et al.
(1997)
FSH, LH, insulin, human
serum
Fresh and
frozen
Primordial to early
antral and
secondary
15–21 days Increased survival and growth
Abir et al.
(1997)
FSH, LH, human serum Fresh Pre-antral to early
antral
14 days Improved survival
Roy and Kole
(1998)
FSH, EGF, TGFb, FCS Fresh Pre-antral 2 days Growth increase by FSH and EGF
Wright et al.
(1999)
FSH, ITS, HSA Fresh Primordial to
pre-antral in cortex
10 days Growth increase
Louhio et al.
(2000)
Insulin, IGF-I, IGF-II, HSA Fresh Primordial to early
pre-antral in cortex
21 days Increased survival and growth
Hreinsson et al.
(2002)
Rat recombinant GDF9,
ITS, HSA
Fresh Primordial to
pre-antral in cortex
14 weeks Increased development of secondary
follicles and survival
Schmidt et al.
(2005)
rhAMH, FSH, LH,
testosterone, ITS, HSA
Frozen Primordial to
pre-antral within
cortex
28 days Increased initiation of growth and
survival of the follicles
Carlsson et al.
(2006a)
Kit ligand, FSH, ITS, anti
c-kit antibody, HSA
Fresh Primordial to early
antral
28 days Oocyte death after blocking Kit
receptor
Carlsson et al.
(2006b)
rhAMH, ITS, HSA Fresh Primordial in
cortex
7 days Inhibition of initiation of growth
Sadeu and
Smitz (2008)
HSA Frozen Primordial to early
antral in cortex
28 days Expression of GDF9 and AMH
Telfer et al.
(2008)
Activin A, ascorbic acid,
HSA
Vitriﬁed Primordial in
cortex, then
isolated
Two-step culture: ﬁrst 6 days in
cortex, then 4 days as isolated
follicles with activin A
Signiﬁcant growth and maturation
from primordial to antral stage
Aghajanova
et al. (2009)
rhAMH, blocking antibody
and receptor blocker, ITS,
HSA
Fresh Primordial to
secondary
14 days Increased development and survival
with GDF9, blocking proved the role
of endogenous GDF9
Garor and Abir
(2009)
FGF2, FCS or HSA, FSH Frozen Primordial to early
antral
28 days Increased E2 production, no effect on
follicle growth
Aghajanova
et al. (2009)
HSA, ITS, TSH or T4 Fresh Primordial and
primary
3 days No effect on follicles, cAMP or ERK
phosphorylation
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mechanisms are typically the ﬁrst to be mentioned; however, the ECM
within and around the follicle regulate numerous cellular processes
associated with follicle development (Irving-Rodgers and Rodgers,
2006; Irving-Rodgers et al., 2009). The ECM is composed of a
variety of molecules, which can include collagens, laminin, ﬁbronectin,
proteoglycans and polysaccharides, though the characterization of the
ECM within the ovary is incomplete (for review Berkholtz et al.,
2006a). In the mouse, collagen I is present throughout the ovary,
with higher concentrations in the ovarian surface epithelium (OSE)
and follicular compartments (for review Berkholtz et al., 2006b). Col-
lagen IV is abundant in the theca cell compartment with low-level
expression in the stroma and granulosa cells. Fibronectin is present
in the stroma and theca cell compartment and increased throughout
follicle development, although its presence in the granulosa cell com-
partment is decreased. Laminin is localized primarily to the theca cell
compartment, with a deﬁned ring at the exterior of the follicular gran-
ulosa cells marking the basement membrane. Low levels of laminin are
also apparent in the stroma and granulosa cell compartment. The
ECM inﬂuences a variety of cellular processes, such as cell mor-
phology, aggregation and communication, proliferation, survival and
steroidogenesis. Additionally, the turnover and remodelling of the
ECM during folliculogenesis suggests that autocrine and paracrine sig-
nalling by secreted ECM molecules can regulate the transitions from
one stage of development to another and ultimately the follicle fate
(Kreeger et al., 2003, 2006).
Principles for choosing an ECM. The complete recapitulation of follicle
growth and oocyte maturation in vitro is a goal that has profound impli-
cations both for discovery-based reproductive science and for patient
health. The process of follicle development is remarkably similar
between small and large animals having short and long reproductive
cycles resulting in one or more mature oocytes. Follicles isolated
from mouse, rat, sheep, cow, pig, non-human primate and human
ovaries begin at a modest size, at roughly 35 mm in diameter for pri-
mordial follicles and 120 mm in diameter for two-layer secondary
structures (for review: Hsueh et al., 2000; McGee and Hsueh,
2000). The ﬁnal follicle diameter around ovulation is 700 mm in the
mouse and around 15–22 mm in the human. The mature oocyte
from these mammalian species is also of similar size ranging from 82
to 110 mm. FSH-dependent follicle maturation from the secondary
stage to a mature follicle takes 72 h in rodents (estrus cycle) and
10–12 days from the small antral stage to the pre-ovulatory stage in
the human (follicular phase of the menstrual cycle) with remarkably
similar patterns of steroid and peptide hormone regulation. The ques-
tion is: what are the in vitro ‘design principles’ that are most important
to the development of in vitro follicle maturation systems and how
these principles might be altered depending on the species from
which the immature follicle is isolated?
A major goal of in vitro follicle culture in follice culture systems centred
around the use of ECM is to maintain the connections between the
oocyte and the somatic cells. We know that the oocyte depends on
the surrounding granulosa cells for metabolic regulation, pH balance
and other small molecules. Thus, the ﬁrst design principle for this
type of approach is the use of a follicle culture matrix that provides
sufﬁcient support to ensure that the somatic cells do not ‘abandon’
the oocyte. A second design principle is that the material supporting
the follicle should be permeable to the media, permitting hormones
to access the follicle structure and factors secreted by the follicle to
be released. A ﬁnal design principle is that the surrounding material
should be amenable to modiﬁcation, including its rigidity and ECM
characteristics. The material we elected to work with is alginate, a
product of seaweed, which has each of these characteristics and has
been used successfully to produce live, healthy offspring in mice
born from in vitro matured follicles and to support growth of non-
human primate and human follicles with the coordinate maturation
of the oocyte (Xu et al., 2009a, b).
Alginate, a translational culture system. The development of culture
systems for follicle development should account for the functions of
the ECM, which are categorized as structural and biochemical (i.e. sig-
nalling). The ECM provides mechanical support to the follicle, which is
essential for maintaining cell–cell contacts and paracrine signalling
between the cellular compartments. Natural (e.g. collagen) and syn-
thetic (e.g. alginate) hydrogels have been employed to maintain the
3D architecture, and have been referred to as 3D culture systems
to differentiate them from traditional 2D culture on ﬂat tissue
.............................................................................................................................................................................................
Table II Sources of human ovarian tissue for evaluation of growth factors.
Source Fresh/
frozen
Advantages Disadvantages
Oophorectomy specimens, Abir et al. (1997) Fresh and
frozen
Large samples may be obtained Advanced age of the donor, often few
follicles
Part of the patient’s frozen tissue, Xu et al. (2009c) Fresh or
frozen
Often good numbers of follicles obtained Reduces the tissue left for clinical use
Transsexuals’ tissue, Van den Broecke et al. (2001) Fresh or
frozen
Many follicles obtained Androgen-treated
Donated biopsy specimens in tubal ligation or
other laparoscopies, Scott et al. (2004a, b)
Fresh or
frozen
Relatively easy to obtain Varying numbers of follicles, infertile
women, no ideal patient group
Tissue from donors who have died, Schmidt et al.
(2005)
Frozen Often good numbers of follicles obtained Rare samples
Donated biopsy specimens from Caesarean
sections, Carlsson et al. (2006a, b; 2009)
Fresh or
frozen
Frequently performed operation, fertile
women, good numbers of follicles obtained
Careful bloodless collection procedure
required, small pieces
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culture surface. Three-dimensional culture systems may have an
advantage in overcoming the difﬁculty of maintaining follicular structure
in early-stage follicles or in follicles from large species. In the case of
human follicles, culture in a 3D collagen gel promoted follicle
growth, whereas follicles on a 2D collagen coated surface maintained
their original size (Abir et al., 2001). In the alginate system, however,
secondary mouse, monkey and human follicles have been able to grow
(Pangas et al., 2003), produce ﬂuid-ﬁlled antral cavities (Xu et al.,
2006a) and produce meiotically competent oocytes (Kreeger et al.,
2005, 2006; Xu et al., 2009a, b), which were successfully fertilized
and implanted to yield multiple live births of healthy mouse pups
(Xu et al., 2006b). The mechanical properties of the 3D matrix
have a signiﬁcant role in supporting follicle development (Xu et al.,
2006b). The hydrogel must have sufﬁcient rigidity to maintain the
3D structure of the follicle, yet must also allow for expansion due
to oocyte growth, granulosa cell proliferation and antrum formation
(Xu et al., 2006a, b; West et al., 2007; West-Farrell et al., 2009).
Forces are generated by follicles in 3D matrices because the
growing follicle exerts an outward force on its surrounding matrix.
The matrix also exerts a force on the follicle, which may affect actin
organization, likely activating one or more of these mechanorespon-
sive pathways. In a 3D system, cell–cell and cell–matrix interactions
are maintained; therefore, a mechanical force applied to the cells at
the exterior of the follicle will be transmitted to all cells within the
follicle to inﬂuence development and maturation.
The signals necessary for follicle development must be presented
within the context of the biomaterial. Diffusible signals (i.e. hormones,
growth factors) can be added to the culture media, and are generally
able to transport through the hydrogel. The ECM regulates cellular
function and differentiation within the follicle in vivo, processes which
are disrupted during follicle isolation. Providing a particular ECM in
an in vitro system allows for an analytical approach to cell and tissue
culture and could therefore lead to a better understanding of
factors determining the quality of the follicle in culture (Kong et al.,
2003; West et al., 2007). Natural materials, such as collagen, are
themselves composed of ECM proteins and provide innate inter-
actions with encapsulated cells. Other matrices, such as alginate, do
not possess these innate interactions and must be modiﬁed to
better mimic the ECM in vivo. In the case of follicle development,
the incorporation of ECM proteins (collagen I and IV, ﬁbronectin
and laminin) or the arginine–glycine–aspartic acid (RGD) peptide
into an alginate matrix affected follicle growth and differentiation, as
well as oocyte quality (Kreeger et al., 2006). The ECM in the 3D
matrix may be useful in maintaining a gradient of paracrine growth
factors essential to polarized growth. Note that the adhesivity of the
hydrogel must be balanced to limit cell migration from the follicle
and into the hydrogel, which can disrupt follicle structure and its
growth potential. Taken together, determining the structural and bio-
chemical design of the ECM for each stage of follicle environment will
facilitate the growth of follicles during 3D culture.
Experience with alginate in mouse and human follicle culture. Secondary
follicles have been isolated from mouse, rat (Heise et al., 2005), non-
human primate (Xu et al., 2009a) and human (Amorim et al., 2009)
ovaries and grown in alginate beads. The hypothesis was that the
microvilli and transzonal projections between the oocyte and
somatic cells would be maintained if follicles were cultured in alginate
(Albertini et al., 2001). Indeed, it has been shown that these mem-
brane extensions are maintained in 3D alginate cultures (Pangas
et al., 2003). The reason why high quality cultured oocytes from the
mouse and healthy germinal vesicle-containing oocytes from the
human are obtained is due to the maintenance of these vital corridors
of communication between the two cellular compartments in the algi-
nate matrix. Heise et al. (2005) demonstrated the presence of connex-
ions between granulosa cells and oocytes in isolated pre-antral rat
follicles cultured in alginate.
New horizons offered by 3D follicle culture systems: Since mouse
follicles can be routinely cultured in this 3D in vitro system, it
becomes possible to address some basic questions about follicle
differentiation in relation to oocyte quality. First, what are the
genes that control follicle selection and activation? What are the sig-
nalling pathways that exist between the oocyte and somatic cells
during terminal follicle development? What signals antrum formation?
What is the earliest follicle stage at which oocytes attain nuclear and
cytoplasmic maturation? What is the role of the somatic cell in fol-
licle development? What controls hormone secretion and what con-
trols the rate of hormone production? What factors are essential for
oocyte development? Very few tissues are able to mature indepen-
dent of a vascular supply; indeed, the follicle is the only known
example of autonomous tissue function. Many new and important
discoveries in follicle biology are made possible by a follicle culture
system that faithfully recapitulates the main feature of the ovary
that contributes to follicle growth, its actual structure as an organ.
Simultaneously, the alginate system is being applied for human follicle
culture (Xu et al., 2009c).
Until recently the work has focused on the secondary follicles stage,
which is in less abundance in adult ovaries but in sufﬁcient prevalence
to be useful to the cancer patient (Xu et al., 2009c). On the basis of
these studies we now know that follicles can be grown autonomous of
the surrounding stroma if sufﬁcient physical support is provided to
them. Whether primordial or primary follicles are independent of
their cellular environment is a question that is currently being
addressed. It is known that the oocyte and somatic cells need constant
communication in order for the oocyte to mature (Albertini et al.,
2001). Finally, these studies show that a rationally designed tissue
engineered approach to follicle maturation is providing new insights
into the physiology of the follicle which can be applied to the cancer
patient setting. Current challenges are to understand better the role
of the gonadotrophins, steroid and peptide hormones in follicle
growth and the integration of hormones with the physical environ-
ment. These fundamental studies will be of great impact for the devel-
opment of a robust system for human follicle development and oocyte
maturation.
Experience with alginate in rhesus monkey follicle culture. Deﬁcits in our
understanding of the processes and factors controlling the onset, pro-
gression and maturation of the human follicle limit our ability to
provide ovary-based options for preserving fertility, including for
women experiencing cancer therapies. Various culture systems men-
tioned earlier in this review and, notably, recent advances that encap-
sulate individual follicles within a permeable matrix (Xu et al., 2006a,
b), have been shown to support mouse follicle development in vitro
and achieve oocyte maturation required for fertilization and pro-
duction of live offspring. Whether such culture systems will support
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similar development of primate follicles has received little attention.
Pre-antral follicles from the marmoset, a New World monkey, devel-
oped to antral follicles and yielded mature oocytes during two dimen-
sional culture (Nayudu et al., 2003). Old World macaques, such as the
rhesus monkey (Macaca mulatta), are a valuable model for studying
the primate ovary, as many of the characteristics and regulation of
cyclic ovarian function are comparable to those in women. For
example, rhesus macaques are monovular and display menstrual
cycles of a month duration, with a 2-week follicular phase. Rhesus
monkeys provide an opportunity to address issues speciﬁc to
primate follicle development relative to rodent follicles, e.g. large
differences in the duration of follicle growth to obtain mature ovula-
tory follicles and possible differences in hormonal and metabolic
requirements. For obvious practical and ethical reasons, it is possible
to address issues in macaques that can only be indirectly studied
with human tissue or in an associative manner.
Therefore, studies were initiated (Zelinski et al., 2008; Xu et al.,
2009a, b) to determine if secondary follicles isolated from adult
female rhesus monkeys, encapsulated in alginate hydrogels and cul-
tured individually in aMEM media supplemented with BSA, bovine
fetuin, insulin, transferrin and selenium, would survive and grow
in vitro. Initial studies addressed three questions: (i) does the stage
of the ovarian cycle at follicle isolation impact follicle development
in vitro? (ii) does the rigidity of the alginate hydrogel inﬂuence follicle
survival and growth? and (iii) do follicles require in vitro exposure to
pituitary gonadotropic hormones?
Our results indicate that secondary follicles isolated from prepubertal
monkeys gave a better survival than fromadult monkeys. Surprisingly the
follicles from the early follicular phase of the menstrual cycle have a
higher survival rate than those collected during the luteal phase. This
difference correlated positively, and may be related to, the larger
mean diameter of secondary follicles in the early follicular versus luteal
phase (270 versus 191 mm). Follicles survived and grew in two hydrogel
conditions (0.5 and 0.25% alginate). The alginate scaffold concentration
affected follicle survival rates and the proliferation and differentiation of
theca and granulosa cells. The higher tested alginate concentrations such
as 1.5 and 1.0% hindered follicle development (Xu et al., 2006a, b). Fol-
licles did not survive in culture in the absence of FSH (recombinant
human FSH; Organon). However, follicle survival up to 30 days in vitro
did not differ between follicles exposed to FSH alone or FSH plus recom-
binant human luteinizing hormone (LH; Merck Serono). Follicles
exposed to either FSH alone or FSH plus LH demonstrated continuous
growth (increased follicular diameter), and approached 1 mm diameter
with an extracellular compartment reminiscent of the antrum within 30
days of culture (Fig. 2). Unexpectedly, follicles cultured with FSH alone
had a greater mean diameter than those cultured with FSH and LH
(750 versus 550 mm; P, 0.05). To consider the steroidogenic function
of these encapsulated follicles during growth in vitro, media sampleswere
assayed for androstenedione (A), E2 and progesterone (P) content.
Steroid levels were low during the ﬁrst week of culture, but increased
5–10-fold (P, 0.05) by 30 days of culture in the presence of FSH
alone or FSH plus LH. Addition of LH tended to increase E and A
Figure 2 Rhesus monkey secondary follicles grown in alginate hydrogel over 3 weeks. Photomicrographs illustrate the morphological and size
changes in follicles during the 24-day culture period. (a) Upon initial isolation and encapsulation in alginate, the oocyte (oo) is centrally located
within a single layer of granulosa cells (gc). A few stromal cells (sc) remain with the follicle. (b) After 15 days in culture, the follicle has increased
almost 20% in diameter. (c) By Day 20, the follicle has more than doubled its original size and a developing antrum can be observed. The oocyte
is no longer centrally located within the follicle. (d, e) By Day 22, the follicle has further increased in diameter and a well-deﬁned antrum can be
seen. (f) On Day 24, the follicle has increased in diameter almost 4-fold, yet retains its spherical morphology and antral cavity, both of which are
supported by the alginate hydrogel. Some follicles (30–50% of those surviving depending upon the culture conditions) achieve diameters typical
of a small antral follicle in the macaque by the fourth week in vitro. Upper left ¼ day of culture; lower left ¼ follicle diameter; lower right
bars ¼ 100 mm. Images on Days 1, 15, and 20 (top row) and of the antrum and oocyte on Day 22 (middle, bottom row) were taken at 20.
Images on Days 22 and 24 were taken at 10. Images from M. Zelinski.
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levels at Day 30 (P ¼ 0.07), and decrease P levels (P, 0.05). Thus, an
alginate hydrogel matrix supports the 3D structure of individual second-
ary follicles from macaques, and permits follicle growth to the small
antral stage within 30 days of culture. FSH, but not LH, is required for
follicle survival and growth, and increased steroidogenesis is associated
with antral development between Days 20 and 30 of culture. LH
increased E and A and reduced P production in the follicle. The effects
of LH activity observed were compatible with data addressing the
needs for LH activity in human in vitro fertilization (IVF) showing a
similar effect upon A/E balance and reduced pre-ovulatory progester-
one production (Smitz et al., 2007).
Ongoing studies are addressing additional questions: (i) will this 3D
follicle culture system support the growth of follicles from young (prepu-
bertal, 4–5 years of age), and older (12 years of age) adult maca-
ques; (ii) does sequential exposure to FSH, followed by FSH plus LH,
promote further follicular growth; (iii) are paracrine factors, such as
AMH, produced by macaque follicles during 3D culture; (iv) what is
the effect of the FSH/LH balance upon oocyte developmental capacity?;
(v) what is the role of theca during in vitro follicle growth on antrum for-
mation and on steroid production; (vi) what oxygen tension should be
applied taking into account the fast effects of oxidative stress and (vii)
how could one evaluate oocyte maturity in a non-invasive manner?
Initial evidence suggests that a greater percentage of secondary fol-
licles from prepubertal animals survive for 30 days in vitro compared
with those from adult monkeys (77 versus 59%; P, 0.05). At collec-
tion, follicle diameters did not differ between prepubertal and adult
animals, but by Day 30, the diameters of growing follicles were
larger if obtained from adults compared with prepubertal animals.
However, an antrum developed by Day 25 regardless of age.
Notably, compared with FSH alone, addition of LH after Day 30
culture increased the diameter of follicles from prepubertal animals
(P, 0.05), but did not affect those from adults (Zelinski et al.,
2008). Further analyses indicated that surviving follicles could be
assigned to three categories according to diameters achieved by
Day 40: no growth (,300 mm); slow growth (301–600 mm) and
fast growth (.600 mm). Although follicle diameters in these groups
did not differ during early culture (Days 1–15), AMH levels in the
media after 1 week were higher for fast growth follicles compared
with no growth follicles (P, 0.05), and after 2 weeks were higher
in fast growth versus slow growth follicles (P, 0.05; Bernuci et al.,
2008). AMH levels peaked at 2 weeks in the presence of FSH and
declined to low levels by 4 weeks of culture (P, 0.05). Thus, AMH
is produced by macaque pre-antral follicles and is associated with
more rapid follicle growth in vitro.
This model could become valuable for understanding the role of
gonadotrophins, steroids and peptide hormones in follicle develop-
ment and its link to oocyte developmental capacity. Once achieved,
this knowledge might be of beneﬁt to human follicle culture and
could be combined with other assisted reproductive technologies to
restore fertility to women, including cancer survivors.
Transplantation of ovarian tissue
Follicle isolation and selection
For patients at risk of ovarian metastatic involvement (e.g. leukemia,
neuroblastoma, breast cancer), alternatives to ovarian tissue fragment
reimplantation need to be considered. However, ovarian tissue
fragments can be reimplanted when the risk of cancerous involvement
of the ovary is absent or minimal, and when autografting would thus
present little or no danger. Indeed, studies evaluating the safety of
cryopreserved human ovarian tissue reimplantation have suggested
that ovarian tissue grafting in Hodgkin’s disease may be considered
safe (Meirow et al., 1998; Kim et al., 2001; Seshadri et al., 2006).
However, in leukemia, malignant cells are present in the bloodstream
and are at risk of being transferred along with the cryopreserved tissue
(Jahnukainen et al., 2001). For this reason, some alternatives have
been under development. Ovarian tissue could be in vitro cultured
for subsequent in vitro follicle culture or used for isolation of pre-antral
follicles from the surrounding stroma that may potentially contain can-
cerous cells. These healthy follicles could then be safely retransplanted
to patients (Dolmans et al., 2007). Obtaining individual isolated fol-
licles has been studied in mice (Gosden, 1990; Eppig, 1994), sheep
(Amorim et al., 2006), goats (Lucci et al., 1999), cows (Figueiredo
et al., 1993), pigs (Greenwald and Moor, 1989) and humans (Oktay
et al., 1997; Abir et al., 1999; Dolmans et al., 2006), but only one
study, in mice, demonstrated fertility restoration after transplantation
of isolated follicles (Carroll and Gosden, 1993).
Since human ovarian cortex is extremely tough to handle, this rules
out mechanical isolation to separate intact primordial follicles. Enzy-
matic tissue digestion using collagenase is currently used for human
ovarian follicle isolation (Oktay et al., 1997; Abir et al., 1999).
However, since collagenase may contain high levels of endotoxins,
which could severely impair culture and grafting outcomes, a protocol
to digest human ovarian cortex using a puriﬁed endotoxin-poor
enzyme (Liberase) has been described to isolate primordial and
primary follicles from ovarian cortical tissue (Dolmans et al., 2006).
Recovery of the isolated follicles is then facilitated by passing the sus-
pension through a Ficoll gradient prior to microscopic examination
(Martinez-Madrid et al., 2004). This technique allows isolation of
large numbers of primordial follicles, with high viability, unaltered mor-
phology and a well preserved ultrastructure (Dolmans et al., 2006).
The viability of these isolated human follicles has been tested by
vital ﬂuorescent dyes (live/dead assays) and in vivo xenografting in a
ﬁbrin clot to the nude mouse ovarian bursa. Their survival and
growth after transplantation was evidenced by their morphologically
normal structure, their progression to more advanced follicular
stages, and their positive staining for human Ki-67 1 week post-
transplantation (Dolmans et al., 2007). Furthermore, recent data indi-
cate that human isolated follicles grafted for 6 months can reach antral
stages, demonstrating the capacity of oocytes to survive and grow
further (Dolmans et al., 2008). Isolation of human follicles could be
done directly after tissue harvesting on fresh ovarian tissue, as it has
been done in experimental studies so far. These isolated follicles
could then be cryopreserved and banked until use, as described pre-
viously with sheep follicles (Amorim et al., 2007). Although the easiest
and most logical way to select is probably to cryopreserve the ovarian
biopsy, in strips or fragments, and thaw them the day of isolation and
grafting, it needs to be investigated whether there could be an advan-
tage in cryopreserving follicles over tissue. The cryoprotectant per-
meation might be more efﬁcacious through a cell suspension than
through tissue blocks.
As this approach has been shown to successfully restore fertility in
mice (Carroll and Gosden, 1993), optimization of follicle isolation and
recovery protocols will allow us to consider its development for
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humans, in cases where the risk of reintroducing malignant cells into
cured cancer patients by ovarian tissue autografting cannot be
excluded. Further focus should be given to the development of sensi-
tive and rapid detection methods for cancer detection in ovarian
stroma. Reseeding puriﬁed follicle fractions, free of cancer cells,
requires new surgical approaches to increase efﬁciency of graft recov-
ery. New artiﬁcial matrices might play a role in this.
Transplantation of ovarian tissue to orthotopic sites: case studies
Cryopreservation of ovarian tissue has proved to be a valuable option
for fertility preservation in young patients at risk of premature ovarian
failure. It is the only option available for prepubertal girls, as well as
women who cannot delay the start of chemotherapy and/or
undergo ovarian stimulation with embryo cryopreservation (Gosden
et al., 1994a; Donnez and Bassil, 1998; Dolmans et al., 2005;
Donnez et al., 2006a).
Approximately 30 cases of autotransplantation of cryopreserved
ovarian tissue to orthotopic sites have been reported worldwide
and eight live births have been published to date (Donnez et al.,
2004; Meirow et al., 2005; Demeestere et al., 2007; Andersen
et al., 2008; Silber et al., 2008b; Piver et al., 2009). Donnez et al.
reported the ﬁrst successful transplantation of frozen-thawed
ovarian tissue resulting in a pregnancy and live birth in 2004. From
his series of seven published autotransplantations of cryopreserved
ovarian tissue, all patients recovered ovarian function within a
period of 4–5 months post-grafting (Donnez et al., 2008). Two tech-
niques were successfully used to reimplant frozen-thawed ovarian
tissue in an orthotopic site: either in a specially created window on
the peritoneum (two steps technique, Donnez et al., 2004) or on
the remaining ovary (Donnez et al., 2006a). When using large tissue
strips (10  4 mm), the ovarian fragments can be sutured onto the
remaining ovary after removal of the native cortex. In case of small
cubes (2  2 mm), they can be placed on the decorticated medulla
and held in place with an absorbable adhesion barrier, itself sutured
to the remaining cortex of the native ovary (Donnez et al., 2008).
Although several live births have been reported after cryopreserved
ovarian tissue transplantation, some important questions remain.
Experimental studies show a considerable decrease in the number
of primordial follicles in grafted tissue. This may be due to hypoxia
and the delay that occurs before reimplanted cortical tissue
becomes revascularized. The loss of primordial follicles in
frozen-thawed ovarian tissue after transplantation is estimated to be
50–65% in some studies (Baird et al., 1999; Nisolle et al., 2000)
and .90% in one study (Aubard, 1999; Nottola et al., 2008). On
the other hand, the primordial follicle pool also appears to be
depleted by follicular activation after grafting. Experimental studies
demonstrated a signiﬁcant increase in the proportion of growing fol-
licles, from ,20% in ovaries before grafting to .70% after grafting
in sheep (Baird et al., 2004), monkeys (Gougeon and Busso, 2000)
and humans (Dolmans et al., 2007). According to Baird et al.
(2004), this massive recruitment of primordial follicles, which also
occurs in cultured fragments, suggests the removal of some inhibitory
mechanisms regulating FSH. Following autotransplantation, the
number of antral follicles and inhibin A secretion are reduced, resulting
in raised basal levels of FSH that may account for the massive recruit-
ment, although the early stage of folliculogenesis can occur in the
absence of FSH and LH. Other factors such as signiﬁcantly reduced
circulating AMH levels, might contribute to the underlying rapid
depletion similar to that described in the AMH knock-out model
(Lie Fong et al., 2008, 2009).
A crucial question is how to prevent this premature activation of the
transplanted follicular pool and whether active angiogenesis can be
induced to accelerate the process of neovascularization in grafted
tissue. Research is actually conducted to evaluate, by oximetry and
electro-paramagnetic resonance, the reoxygenation and revasculariza-
tion of human ovarian xenografts in order to have objective par-
ameters to monitor the revascularization process (Van Eyck et al.,
2009a, b). Indeed, these studies have shown that revascularization
of avascular grafts are only complete on Day 10 post-grafting, and
that the follicle pool remains anoxic for 5 days.
Another important question is how to improve oocyte quality in
frozen-thawed transplanted tissue. A study recently presented by
Dolmans et al. (2009) reported a higher risk of empty follicles, abnor-
mal or immature oocytes and low embryo transfer rates in patients
with cryopreserved autotransplanted ovarian tissue. In this IVF
series, 21 oocyte retrievals yielded 16 oocytes, 10 of which were in
metaphase II (MII). Five MII oocytes successfully fertilized with
normal subsequent embryo development, but no pregnancy occurred.
Women who have undergone grafting of frozen-thawed ovarian tissue
have reduced ovarian reserves and elevated FSH concentrations, and
there is frequently a failure to recover oocytes in the aspirates from
follicles from these patients. This might arise from the inappropriate
activation of granulosa cells and oocytes by increased FSH concen-
trations, which could provoke an asynchronous maturation. Another
hypothesis to explain the prevalence of empty follicles is that the
oocytes have been damaged by the cryopreservation, thawing and
transplantation procedures.
Finally, the standard method for human ovarian tissue cryopreserva-
tion is slow programmed freezing, using HSA-containing medium with
either propanediol, dimethylsulphoxide or ethylene glycol as a cryo-
protectant, combined or not with sucrose. Vitriﬁcation is still at the
experimental stage for human tissue, but appears to yield promising
results (Kagawa et al., 2009; Keros et al., 2009).
In conclusion, live births obtained after transplantation of
frozen-thawed ovarian tissue in humans give hope to young cancer
patients, but the techniques can be improved at several levels.
Research programmes need to determine the ideal fragment size for
cryopreservation and transplantation, whether active angiogenesis
can be induced to accelerate the process of neovascularization in
grafted tissue, and whether oocyte quality is affected by the freezing
and grafting procedures applied.
Techniques for safeguarding fertility in rare
animal species
All felid species in the wild are near extinction
Aside from their application to fertility preservation in humans, the
studies described above raise the hope that advances in culture and
cryopreservation of ovarian tissue may provide a valuable tool for
assisted reproduction in rare and endangered species.
Of the 37 felid species, all but the domestic cat are threatened
worldwide and face extinction in all or part of their native habitats
(CITES-appendices, www.cites.org). In some species, a greater
number of individuals are present in zoo facilities than in their
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natural habitats. Advanced reproductive techniques (e.g. IVF and
embryo transfer) are undoubtedly powerful tools for safeguarding
rare and endangered felid species (Wildt et al., 1992; Jewgenow
et al., 1997; Pope et al., 2006), but the most critically limiting factor
to their application is the lack of mature and fertilizable female germ
cells (Jewgenow and Paris, 2006). This problem could be addressed
by accessing the large source of oocytes available within the pre-antral
and primordial follicles in the ovarian cortex and culturing them to
maturity in vitro. In this respect, ovarian tissue from wild cats that
must be spayed or that either die suddenly or be euthanized for
medical reasons, may serve as an oocyte pool for rescuing the valuable
genetic potential of females and subsequently aid in the propagation of
these species.
The domestic cat as a model for in vitro culture and transplantation
The full-term culture of primordial follicles to a mature stage and the
birth of viable offspring after IVF and embryo transfer have not yet
been achieved in a felid species (Jewgenow and Pitra, 1993; Jewgenow,
1996, 1998; Jewgenow and Paris, 2006). Therefore, transplantation of
ovarian tissue in a xenogeneic host is discussed as an long-term
alternative method for follicle growth and development (Jewgenow
and Paris, 2006). Gosden et al. (1994b) ﬁrst reported the xenotrans-
plantation of fresh ovarian tissue of domestic cat in SCID mice. Trans-
plant survival as well as the development of antral follicles was
documented up to 9 months after grafting at autopsy. More recently,
Bosch et al. (2004) showed antral follicle stages following xenografting
of cortex fragments from frozen/thawed domestic cat ovaries in SCID
mice by post-mortem histology 2 months after grafting. Fassbender
et al. (2007) demonstrated that fresh ovarian cortex from domestic
cats survived xenotransplantation in athymic nude rats and that high
resolution ultrasonography provided a reliable method to follow xeno-
graft survival and follicular development within the grafts. It turned out
that this technique is suitable to assess the efﬁciency of hormonal
treatments and to narrow the optimal time frame for oocyte retrieval
in living recipients. The success of all ovarian tissue transplantation,
independent of the tissue status (fresh or frozen) is highly dependent
on the time point of oocyte retrieval to ensure maturation and sub-
sequent IVF trails, particularly if the donor ovary originated from a
rare and valuable animal. Unfortunately, the existing protocols for
ovarian cryopreservation and grafting are species-speciﬁc and most
protocols only apply to just a few species (humans and laboratory
animals). A network of research in a broad diversity of species is
required to develop and apply cryobanking technology to felid conser-
vation. Development of cryopreservation protocols speciﬁcally for
felids will impact a number of other threatened cat species worldwide,
and a concerted, integrated effort to conserve critically endangered
European carnivores is urgently needed.
Discussion
Surveys of cancer survivors have identiﬁed an increased risk of emotion-
al distress in those who become infertile because of their treatment
(Berkowitz K., 2003; Partridge et al., 2004; Carter et al., 2005). Loss
of fertility potential is something difﬁcult to understand for young
children, but is potentially traumatic to them as adults. It is considered
good clinical practise that all cancer patients of reproductive age
be informed about the possibility of treatment-related infertility.
Professional societies recommend that oocyte and ovarian tissue cryo-
preservation be performed only in centres with demonstrated exper-
tise using only IRB-approved protocols [British Fertility Society (BFS):
http://www.britishfertilitysociety.org.uk; European Society of Human
Reproduction and Embryology (ESHRE): http://www.eshre.com;
American Society for Reproductive Medicine (ASRM): http://www
.asrm.org; American Society for Clinical Oncologists (ASCO): http://
www.asco.org). Guidance documents stress that this ﬁeld of medicine
is still considered to be experimental. Although the practice of oocyte
and ovarian tissue cryopreservation has been spreading rapidly,
there has been almost no research effort directed towards future
use of this tissue.
In view of the rapid introduction of fertility preservation in clinical
practice, organization of the ﬁeld in a more professional way has
become a high priority.
As cancer treatments evolve rapidly, so should current understand-
ing on their impact on female fertility, so that clinicians can provide
their patients with the most accurate information about their risk of
infertility related to cancer treatment (Jeruss and Woodruff, 2009).
Most of the available literature documenting cancer treatment-related
infertility risks reports rates of azoospermia and amenorrhea, which
are surrogate markers of limited practical value. There are better bio-
chemical markers of fertility, such as AMH and non-invasive imaging
techniques (ultrasound, Doppler, magnetic resonance) that allow a
more precise evaluation of the damage to the reproductive organs
(ovary, testicle, uterus; van Beek et al., 2007). A follow-up of all
cancer patients that receive potentially gonadotoxic drugs with these
investigative tools must be recommended in order to gather precise
information on the following questions: what cancers directly affect
fertility? Which cancer drugs should be avoided in girls and premeno-
pausal women because of their gonadal toxicity? Which combination
of drugs should be banned for negative effects on the ovary and
uterus?
In most countries, patients are followed up by oncology but receive
no expert advice from a fertility specialist as part of the patient man-
agement protocol. Newer techniques, such as AMH measurements,
would allow a better appreciation of post-treatment fertility potential
(Lie Fong et al., 2008, 2009). Providing adequate support and funding
for regional or national ‘fertility preservation banks’ would allow better
organization and coordination of patient follow-up.
Restoration of fertility after cancer
by transplantation techniques
It was estimated that 20% of grafted ovarian tissue cases led to child-
birth in the ﬁrst reported series worldwide, which is an encouraging
ﬁgure. However, there is still a lot to do towards improving the tech-
niques for grafting of ovarian tissue or isolated primordial follicles.
More speciﬁcally, new approaches to the revascularization of the
grafted tissue are needed, with the goal of reducing the number of fol-
licles that die within the ﬁrst hours after transplantation by ischemia.
As the clinical beneﬁt of transplanted ovarian cortical pieces is directly
proportional to their longevity, useful information can be gained from
recent work by Silber and Gosden (2007) and by Silber et al. (2008a,
b). Ovarian cortex transplantation between monozygotic twin sisters,
where ovarian tissue transplants had not been frozen before grafting of
the thinned cortex using a microsurgical technique provide evidence
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that it is now technically possible to restore ovarian function within 4
months post-surgery, to obtain pregnancies within a median period of
15 months and for healthy babies to be born. Two to four years post-
transplantation of on average 30% of cortical tissue from the donated
ovary, the acceptors were still menstruating and some patients had
even had a second child from the graft.
Pioneering work on transplantation of previously cryopreserved
human ovarian tissue in a heterotopic site such as a subcutaneous
location (Oktay et al., 2001; Callejo et al., 2001; Oktay et al., 2003)
or in the space between the rectus sheath and rectus muscle (Kim
et al., 2009) has proven that follicular function can be recovered and
this research has led to the development of several technical improve-
ments. However, until now only a few intact oocytes could be recov-
ered over several ‘cycles’ from the developed follicles in the transplant
(Oktay et al., 2004; Kim et al., 2009). These oocytes fertilized normally
and a few embryos developed in vitro. Of the few patients that had
consented to undergo heterotopic grafting, none have become
pregnant.
Many other challenges are remaining in the ﬁeld of transplantation,
to determine the optimal site for grafting ovarian tissue or its isolated
follicles (Donnez et al., 2006b; Demeestere et al., 2009), and to
restore ovarian function after transplantation of frozen-thawed
whole ovary (Jeremias et al., 2002; Salle et al., 2002; Arav et al.,
2005; Courbiere et al., 2005; Imhof et al., 2006; Martinez-Madrid
et al., 2007).
Until today, only a few patients (+1%) who have been declared
cancer-free have come back with a request for reimplantation of
ovarian tissue, so our experience is still very limited. The amount of
data on the quality of oocytes after the combined procedures of cryo-
preservation and transplantation is lacking. Basic knowledge regarding
neovascularization, reinnervation and paracrine and autocrine
regulation is still very scarce, and basic research efforts in these
areas requires support in order to overcome some of the challenges
that limit the success of the transplantation.
Advances and challenges with tissue and
follicle culture techniques
Signiﬁcant progress has been made in improving the methods for
in vitro growth and maturation of ovarian follicles from a range of
species including rodents, ruminants, primates and humans (Xu
et al., 2006b; Nogueira et al., 2008; Picton et al., 2008; Sadeu et al.,
2008; Xu et al., 2009a, b). A strategy to maximize the reproductive
potential of fresh and cryopreserved human ovarian tissue used in fol-
licle culture strategies must be orientated around the activation and
sustained in vitro growth of primordial, primary or secondary follicles,
as these follicles are all in the human ovarian cortex. In this context,
although long-term ruminant and primate follicle culture systems are
a better model for human follicle culture than shorter term rodent fol-
licle culture systems, ultimately the best model for the therapeutic
derivation of fertile human oocytes is a human follicle culture
system. Human follicle culture systems must work equally effectively
in both fresh and cryopreserved ovarian tissues (Newton et al.,
1999; Muruvi et al., 2005, 2009; Xu et al., 2009b).
Progress in the development of systems for the derivation of mature
human oocytes from immature follicles in vitro is hampered by the very
limited availability of accurate biological information on the genes and
growth factors that initiatal follicle growth and support follicle and
oocyte development to maturity in vivo in humans (Picton, 2001; Xu
et al., 2006a; West et al., 2007). A non-limitative list of current knowl-
edge gaps on basic biological mechanisms related to in vitro oocyte
growth is shown in Table III. Making signiﬁcant progress in
.............................................................................................................................................................................................
Table III Current gaps and opportunities in follicle and oocyte in vitro culture.
Component Controversy
Follicle harvest strategy Isolated follicle culture versus in-situ or in ovo culture systems
Follicle attachment system Use of adherent versus non-adherent culture systems
Follicle growth strategy Use of linear (2D) versus spherical (3D) culture systems
Culture matrix Inclusion versus exclusion of matrix and/or scaffolds to support 3D culture and antrum formation
Culture system continuity Use of consistent system for all stages of follicle growth development versus sequential, follicle phase-dependent systems
Base media Optimization of base media and buffering systems to suit species and culture strategy
Oxygen tension Use of high (20%) versus low (5–6%) oxygen tensions
Media supplementation Use of serum-based versus deﬁned serum-free media
Developmental timeframes Use of accelerated versus protracted growth systems
Growth additives Supplementation of media with pharmacological versus physiological doses of growth additives
Hormonal additives Supplementation of growth media with FSH and/or LH and estrogen and/or androgens
Metabolic requirements Use of continuous versus sequential systems that modify the culture environment to meet the changing metabolic requirements of
follicles and oocytes during in vitro growth and maturation
Culture starting and end
points
Optimal initial and terminal size for oocytes and follicles at the start and end of follicle culture, species dependent
End-point measures Agreement on best end-point measures, including morphology, viability assays, follicle and oocyte dimensions, growth rates,
hormone secretion, cell signalling, molecular markers, IVM, fertilization, embryo production and live births
Normality testing Agreement on how and what markers to measure to deﬁnitively test the normality, methylation and epigenetic programming,
fertility and developmental competence of in vitro cultured oocytes and the embryos they produce
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understanding which factors regulate the early stages of follicle devel-
opment requires the availability of costly high-tech infrastructure,
including laser capture microdissection, quantitative PCR, confocal
microscopy and DNA microarrays. It is important that the conse-
quences of extended follicle culture and the use of assisted reproduc-
tive technologies on key programming events during oogenesis and
embryogenesis can be apprehended (Pesty et al., 2007; Huntriss and
Picton, 2008; Anckaert et al., 2009a, b). Research also needs to evalu-
ate the metabolic requirements that support acceptable rates of
somatic and oocyte growth in vitro and how these demands change
as oocyte and follicle development progress (Harris et al., 2007,
2009; Harris and Picton, 2007). Ultimately, the information gained
from this fundamental research must be applied to the biological
and practical problems associated with human follicle culture.
Typical biopsies obtained for research are often from women over
35 years with gynecological pathologies and these tissues are inhomo-
geneous due to age-related follicle depletion. It is difﬁcult to obtain
cortical ovarian tissue from young patients for experimentation.
Active recruitment of young and fertile tissue donors (e.g. at the
time of Caesarean section) should be encouraged and the spare
tissues and cells from IVF laboratories should be collected and prop-
erly stored for use in research (Schubert et al., 2008). Other possible
sources of research material for culture are human fetal ovarian tissue
(therapeutic abortion material obtained from prenatal diagnostic units)
and ovarian tissue from consenting cancer patients (Sadeu et al.,
2006). This material can be obtained via collaboration with a prenatal
diagnosis unit and through operative laparoscopists.
Today, a number of different culture systems have been developed
that have been partially or fully optimized for a range of different
animal models (Picton et al., 2008). Although some systems are
more advanced than others, no one system is fully optimized for
the complete in vitro growth and maturation of human follicles and
oocytes. The variety in system development is vital at this stage in
the evolution of human follicle culture as each of the different pub-
lished systems have strengths and weaknesses that may be usefully
exploited to meet the challenges of human follicle culture. A good
example of this is the recent development of the alginate systems
detailed in this review that have been shown to be an effective
vehicle to support the three dimensional growth of pre-antral to
antral staged murine follicles with the production of live offspring
(Xu et al., 2006b; West et al., 2007). In contrast, a physiological,
serum-free culture system has also been shown to be highly effective
in supporting antral cavity formation and the production of mature,
fertile ovine follicles and oocytes in the absence of any ECM
support (Newton et al., 1999). It is likely that the great majority of
the advances made in follicle culture with small animals will not
prove to be robust enough to be scaled-up to meet the challenges
of extended human follicle growth in vitro. At the time of writing,
many fundamental biological approaches (Table III) are being scruti-
nized. For example, there is no clear agreement between follicle
culture practitioners within or across species on the efﬁcacy and
safety of serum-based culture systems supplemented with pharmaco-
logical levels of growth additives (Picton et al., 2008) or of the more
challenging, but consistent, serum-free culture systems supplemented
with low doses of additives (Newton et al., 1999), based on the phys-
iological requirements to support somatic cell interactions and differ-
entiation (Campbell et al., 1996; Picton et al., 1999a, b) and gamete
maturation in vitro (Wynn et al., 1998; Nogueira et al., 2003, 2006;
Sutton et al., 2003; Gilchrist and Thompson, 2007; Romero and
Smitz, 2008, 2009) in a number of species.
Challenges to fertility preservation research
funding in Europe
Studies on early embryogenesis in humans should be allowed as this is
the only way to reliably evaluate current fertility preservation tech-
niques. Spare oocytes from human IVF/ICSI practises should be cana-
lized to a dedicated research laboratory to make optimal use of this
rare material. In light of the few human oocytes available and the
associated ethical considerations, difﬁcult molecular techniques may
be used to evaluate genetic and epigenetic damage on well-validated
animal models, including mice and larger animals such as the cow,
sheep, goat or pig.
A major hurdle which remains to be tackled in the context of
human follicle culture is the need for comprehensive testing of
human oocytes derived by in vitro growth and maturation. The mol-
ecular and epigenetic programming and chromosomal health of
in vitro derived human MII oocytes, as well as the fertility of these
gametes and evaluation of all aspects of the health, molecular and
genetic normality and developmental competence of the embryos
they produce, must be tested to quantify the risks of long-term
culture. The testing of the health of human oocytes and the
embryos they produce is fraught with technical and ethical challenges
that must be overcome before in vitro derived human gametes can be
used safely to treat patients. Until further extensive research has been
conducted, the potential of in vitro oocyte growth and maturation
technologies remains to be realized.
A template for the European program is the U.S.-based Oncofer-
tility Consortium, which includes experts from Europe on its advisory
board and is involved in all aspects of fertility preservation research
from the fundamentals of follicle maturation to the ethics, legal and
economic complexities facing the patients and providers. The devel-
opment of a sister-EU based Oncofertility Consortium will provide
worldwide strength by bringing experts together to solve common
problems and reduce the time to development of strong technol-
ogies. Indeed, the ﬁrst step in this process has occurred with the
ESHRE and ASRM liaison board agreeing to support the ﬁrst ever
meeting on the topic of Oncofertility at the World Health Organiz-
ation (WHO) to be held September 2010 at Northwestern Univer-
sity in Chicago. This uniﬁcation of purpose will advance the pace and
quality of research in a signiﬁcant manner and ensure that the
patients who are storing their tissues today will have an opportunity
to use them in the future.
Development of a central European database on ‘assisted repro-
duction after cancer’ and a Web site with the addresses of the
Centres with expertise in the ﬁeld should be accessible to all pro-
fessional bodies and patients from the European Community. A Euro-
pean equivalent to the US Web site ‘www.myoncofertility.com’, which
is sponsored by the NIH, should be organized on a multinational level.
ESHRE, as the largest European Society fostering advances in the ﬁeld
assisted reproduction, will need to take the initiative in driving a multi-
disciplinary multinational collaboration via its Task Forces in ‘Basic
Science in Reproduction’ and ‘Fertility Preservation’ and involve
most of its Special Interest Groups (www.eshre.com).
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Conclusion
In short, we have convened to discuss a matter of urgency for young
women facing a life-preserving but fertility-threatening cancer treat-
ment. We have identiﬁed the opportunities and the gaps in our ﬁeld
both at the basic and translational levels. We have clear ways to
tackle the problems and take advantage of the opportunities.
Central to this program is the strong collaboration of a global team
of investigators and clinicians working on the maturation of the
ovarian follicle. This unprecedented team has convened at an unpre-
cedented time—more and more young cancer patients are surviving
their disease. Our work will ensure that not only do we learn more
about follicle development, but we provide appropriate options to
these people who are banking their ovaries on the notion that we
will succeed in our work.
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